Market Herald logo


Be the first with the news that moves the market
  • Bod Australia has dispensed 549 MediCabilis prescriptions in September 2019 – a 224 per cent increase from July
  • 1158 prescriptions have been dispensed so far in CY2019
  • MediCabilis is now being used to treat 17 different conditions such as chronic pain and neurological diseases

Bod Australia has witnessed continued considerable medicinal hemp growth throughout September for its MediCabilis CBD product.

Bod announced that it had dispensed 549 MediCabilis prescriptions in September 2019, which represents a 224 per cent increase on July’s prescription of 169 and a 67 per cent increase from August’s 329.

Bod has also advised that its MediCabilis product is now being used for up to 17 different conditions including chronic pain, post traumatic stress disorder and neurological diseases.

The Board and management are confident that growth will continue in the coming months as MediCabilis is prescribed for additional medical conditions and as additional markets jump on board.

“The ongoing growth that Bod is witnessing in medicinal cannabis as MediCabilis is prescribed for additional medical conditions and as additional international market entries are progressed,” CEO Jo Patterson said.

“The repeat presciprdtions which are underpinning growth also shows that there is considerable satisfaction from patients and also confidence in the product in the medical community,” Jo added.

It has also seen considerable growth in the number of physicians prescribing the product, and Bod expects continued growth of these metrics over the upcoming months through educational and outreach initiatives.

Bod has been witnessing continued repeats in prescriptions which further highlight physician and patient product satisfaction.

Of the patients who are using MediCabilis for chronic pain, 35 per cent have filed a repeat prescription and a further 59 per cent who are using it for epilepsy and seizures had a repeat purchase.

Bod has estimated that one in three patients are using MediCabilis more than once.

In late July 2019, Bod’s share price reached an all-time high of 69 cents apiece, today shares are trading for 45.5 cents in a market cap of $38.73 million.

BDA by the numbers
More From The Market Herald
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp (ASX:RAP) completes recruitment for Indian COVID-19 study

ResApp Health (RAP) has completed the recruitment ahead of schedule for its Indian COVID-19 clinical study.